Co-Diagnostics (CODX) has announced a reverse stock split at a ratio of 1-for-30 shares, effective on January 2, 2026. This move aims to regain compliance with the $1.00 minimum bid price requirement for listing on The Nasdaq Capital Market. The new CUSIP number post-split will be 189763 204. Source: TheFly.

For more information on top-performing stocks, visit TipRanks.

Disclaimer & Disclosure: For more information on Co-Diagnostics, visit TipRanks.

Read more at Yahoo Finance: Co-Diagnostics announces 1-for-30 reverse stock split